Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
News information

Medicilon congratulate NeuPharma's New Drug to initiate the first-in-human Phase I Clinical Trial

2015-06-11
|
Page View:

Suzhou NeuPharma Co., Ltd announced that it has initiated the first-in-human Phase I clinical trial of RX108 in Australia.  RX108 is a novel small-molecule inhibitor of sodium-potassium adenosine triphosphatase.  The toxicology services, that Medicilon provided, speeded up the process of the trial.  The trend for drug discovery nowadays is the collaboration between pharmaceutical company and CRO.  The collaboration will speed up the process and lower the cost.

分享到:
Relevant newsRelevant news